Institutional Investor RTW Investments Increases Potential Stake in Orchestra BioMed to 19.7%
OBIO sits 98% above its 52-week low of $2.2.
Summary
RTW Investments increased the maximum exercisability of its pre-funded warrants, leading to a deemed beneficial ownership of 19.7% of Orchestra BioMed, including an additional 3.6 million shares.
Key Events · Ownership and Investor Activity · OBIO
-
Increased Warrant Exercisability
RTW Funds submitted notices to the Issuer increasing the Maximum Percentage under their Pre-Funded Warrants from 9.99% to 19.99%.
-
Significant Deemed Ownership Increase
This adjustment results in the Reporting Persons being deemed to beneficially own an additional 3,636,363 shares of common stock.
-
Total Beneficial Ownership
RTW Investments, LP and its affiliates now beneficially own 11,942,426 shares, representing 19.7% of the outstanding common stock.
-
No Recent Transactions
The filing explicitly states that none of the Reporting Persons have effected any transactions with respect to the Issuer's securities during the past sixty days.
Analysis · OBIO · Industrial Applications And Services
RTW Investments, a significant institutional holder, amended its Schedule 13D to reflect an increase in the maximum percentage for its pre-funded warrants from 9.99% to 19.99%. This technical adjustment allows RTW to be deemed to beneficially own an additional 3.6 million shares, bringing their total potential beneficial ownership to 19.7% of Orchestra BioMed. While not an immediate share purchase, this move indicates RTW's continued flexibility and potential to increase its stake in the company, signaling ongoing interest from a major investor.
At the time of this filing, OBIO was trading at $4.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $245.6M. The 52-week trading range was $2.20 to $5.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.